[HTML][HTML] Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
AA Secord, DM O'Malley, AK Sood, SN Westin… - Gynecologic …, 2021 - Elsevier
Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
AA Secord, DM O'Malley, AK Sood… - Gynecologic …, 2021 - pubmed.ncbi.nlm.nih.gov
Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
AA Secord, DM O'Malley, AK Sood… - Gynecologic …, 2021 - ohiostate.elsevierpure.com
Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
DM O'Malley, AK Sood, SN Westin, JF Liu - Gynecologic Oncology, 2021 - europepmc.org
Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
[HTML][HTML] Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
AA Secord, DM O'Malley, AK Sood… - Gynecologic …, 2021 - gynecologiconcology-online.net
Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
AA Secord, DM O'Malley, AK Sood… - Gynecologic …, 2021 - mdanderson.elsevierpure.com
Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …
[引用][C] Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
AA Secord, DM O'Malley, AK Sood, SN Westin… - Gynecologic …, 2021 - cir.nii.ac.jp
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial
ovarian cancer: A review | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
ovarian cancer: A review | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …